|Bid||74.63 x 3000|
|Ask||74.63 x 1100|
|Day's Range||74.39 - 75.27|
|52 Week Range||65.25 - 87.80|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||26.82|
|Forward Dividend & Yield||2.60 (3.49%)|
|Ex-Dividend Date||Mar 12, 2021|
|1y Target Est||N/A|
There's going to be a change in leadership at Merck (NYSE: MRK) with CEO Ken Frazier retiring as of June 30 and Robert Davis, who currently serves as the company's CFO, taking over. In this video from Motley Fool Live, recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss Frazier's decade-long stint in the corner office and what investors should expect as Davis takes over. Brian Orelli: Moving onto Merck, the ticker there is MRK.
Pfizer announced a plan to split into three separate businesses in a major restructuring move. Here's what you need to know.
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]